![Show Menu](styles/mobile-menu.png)
![Page Background](./../common/page-substrates/page0023.png)
Page 67
allied
academies
September 20-22, 2017 | Toronto, Canada
10
TH
AMERICAN PEDIATRICS HEALTHCARE &
PEDIATRIC INFECTIOUS DISEASES CONGRESS
Pediatric Healthcare & Pediatric Infections 2017
Introduction:
Corticosteroids are the main therapy of
nephrotic syndrome and goal of corticosteroid therapy is
to obtain maximum clinical benefit with minimum adverse
effects. Children are more vulnerable to side effects of
corticosteroids related to growth and adrenal suppression
so a search for an alternative steroid with fewer side-
effects is underway. Deflazacort is an oxazoline derivative
and preliminary data suggest reduced osteoporosis, lesser
growth retardation and weight gain with deflazacort. This
study was done to compare the effectiveness and safety of
deflazacort in idiopathic nephrotic syndrome.
Methods:
Twenty five children with age between 2 to 12
years, with idiopathic nephrotic syndrome were enrolled.
They were randomly assigned to receive Deflazacort (Group
A, n=12) or Prednisolone (Group B, n=13) and were followed
up for six months.
Results:
All children of group A and 11 of group B had
remission. Two children from group B were steroid resistant.
Mean time taken to induce remission was significantly
(P=0.012) less in group A (10.25±2.41 days) than group B
(12.55±1.44 days). One patient in group A had relapse on
follow up as compared to 3 in group B (P=0.58). Statistically
significant difference (P=0.03) in change in mean height was
found between group A (2.13±0.50cm) and B (1.44±0.45cm),
with group B gaining less height.
Conclusion:
Remission rate in both groups was comparable
although time taken to induce remission was shorter in
Deflazacort group and there was a significant difference in
change of mean height on follow up with Prednisolone group
gaining lesser height
e:
p.sadbhavna@yahoo.comDeflazacort versus prednisolone: Randomized controlled trial in treatment of children with idiopathic
nephrotic syndrome
Pandit Sadbhavna, Singhal Ravish
and
Dhawan Neeraj
Government Multi Speciality Hospital, India